Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Small Cell Lung Carcinoma 4Lung Neoplasms 3Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1HRD Cancer 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Bevacizumab 39Paclitaxel 35pembrolizumab 27Carboplatin 27Specimen Handling 21olaparib 19Magnetic Resonance Spectroscopy 19Gemcitabine 19liposomal doxorubicin 17Cyclophosphamide 16niraparib 13fludarabine 12Topotecan 12Cisplatin 12Biopsy 12Taxes 9Nivolumab 8Immunoglobulin G 8Fulvestrant 8Doxorubicin 8Disulfides 8Surveys and Questionnaires 7palbociclib 6aldesleukin 6Oxaliplatin 6Letrozole 5Fluorouracil 5trastuzumab deruxtecan 4oregovomab 4mirvetuximab soravtansine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × berzosertib × 90 days × Clear all
NCT02595892 2026-04-13

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02627443 2026-04-13

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
35 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡